Quantifying Ocular Besifloxacin with LC–MS–MS
A new liquid chromatography tandem mass spectrometry (LC-MS-MS) method has been developed to study besifloxacin, which is used to treat bacterial conjunctivitis.
Photo Credit: Lew Robertson/Getty Images
A new liquid chromatography tandem mass spectrometry (LC-MS-MS) method has been developed to study besifloxacin, which is used to treat bacterial conjunctivitis.1 Besifloxacin, along with other fluoroquinolones, is used to treat a wide range of ocular infections. However, the overuse of the fluoroquinolone class of antibiotics puts them at high risk of bacteria developing resistance to them.
Besifloxacin, developed specifically for ophthalmic use, displays potent efficiency against a wide range of Gram-positive and Gram-negative ocular pathogens, including multi-resistant strains. This complex mode of action and rapid distribution within ocular tissues theoretically reduces the risk of resistance making besifloxacin important pharmaceutically.
Two chromatographic methods were previously developed to study besifloxacin; however, both the chiral high performance liquid chromatography (HPLC) and HPLC with UV detection methods were insufficient according to the Chinese authors and did not meet the desired sensitivity, speed, and throughput in bio-sample analysis.
The new method developed for quantification of besifloxacin in ocular and plasma tissues used LC-MS-MS to reach the desired analytical requirements.
Tissues were obtained from rabbits and analyzed using this new method. The lower limit of quantification for besioflaxin was 0.103 ng/mL for plasma and 2.06 ng/mL for other ocular tissues with good accuracy, precision, and a short run time of 3.0 min. This was across single and multiple topical applications.
According to the authors, this method was rapid and reproducible and therefore suitable for the pharmacokinetic study of besifloxacin. - L.B.
References
1. X.F Gu et al., J. Pharm. Biom. Anal. 117, 37-46 (2016).
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
